AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01495195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose donepezil
Description: Donepezil titrated to 10 mg daily
Study NCT01691898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
Study NCT01691898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: RTX 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle.
Study NCT03285984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 67% Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride
Description: Toothpaste containing 67 percent (%) Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride
Study NCT03285984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride
Description: Toothpaste containing 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride
Study NCT03285984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium
Description: Whitening Toothpaste containing 62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium
Study NCT01495195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline
Description: Transdermal selegiline, 6 mg daily
Study NCT03285984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride
Description: Toothpaste containing 0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride
Study NCT00920634 — intervention group
Intervention type: DRUG
Intervention: Follitropin beta
Description: For subcutaneous or intramuscular injection, the usual dosage is 50 IU of follitropin beta (recombinant) once daily for 7 days. The dosage should be adjusted subsequently while monitoring the development of follicles (dose increase by 25 IU every 7 days if the response of the ovaries is poor) and, after confirming presence of follicles of 18 mm or larger in mean diameter by the ultrasonic tomography, ovulation is induced by the administration of a human chorionic gonadotropin preparation.
Study NCT00413244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AndroGel 5 Grams
Description: Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.
Study NCT00413244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.
Study NCT02019277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Dosing regimen to be determined by the investigator, routine clinical practices.
Study NCT02019277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Dosing regimen to be determined by the investigator, routine clinical practices.
Study NCT02019277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Dosing regimen to be determined by the investigator, routine clinical practices.
Study NCT02019277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg as an IV infusion every 3 weeks.
Study NCT02019277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered at a fixed dose of 600 mg SC every 3 weeks.
Study NCT04764773 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04110678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NeuroEPO
Description: NeuroEPO \[CIMAB S.A, Havana, Cuba\]
Study NCT04110678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NeuroEPO
Description: NeuroEPO \[CIMAB S.A, Havana, Cuba\]
Study NCT00395733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: Participant received a single intravenous injection with Gadobutrol (1.0 M) at a volume of 0.2 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.3 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
Study NCT00395733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentate dimeglumine (Magnevist, BAY86-4882)
Description: Participant received a single intravenous injection with Gadopentate (0.5 M) at a volume of 0.4 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.6 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
Study NCT01495195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose
Study NCT03509285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam Placebo
Description: 100 mg lactose tablets
Study NCT03509285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cenobamate placebo
Description: Sugar pill manufactured to mimic cenobamate 100 mg tablet
Study NCT02534896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment I
Description: Sunpharma1505 and Placebo
Study NCT02534896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment II
Description: Sunpharma1505 and Placebo
Study NCT02534896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment III
Description: Reference1505 and Placebo
Study NCT03509285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cenobamate placebo
Description: Sugar pill manufactured to mimic cenobamate 100 mg tablet
Study NCT01411618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: free alcohol essential oil mouthwash
Description: All subjects were instructed to rinse twice a day, in the morning and in the evening, with 20 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
Study NCT01411618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: free alcohol essential oil mouthwash
Description: All subjects were instructed to rinse twice a day, in the morning and in the evening, with 20 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
Study NCT01931618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online screening and feedback
Description: An online single session screening procedure including individualized normative feedback.
Study NCT03509285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate placebo
Description: Sugar pill manufactured to mimic cenobamate 100 mg tablet
Study NCT01575470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow mononuclear cells
Description: bone marrow harvest (5ml/kg of body weight) performed within 36 hours of injury, followed by single intravenous infusion of bone marrow mononuclear cells.
Study NCT00711646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex®
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
Study NCT00711646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
Study NCT03728738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Head of Bed Positioning
Description: The head of bed (HOB) position will be selected through computerized randomization, and will include either zero degree positioning or thirty degree HOB elevation
Study NCT01931618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online screening and feedback
Description: An online single session screening procedure including individualized normative feedback.
Study NCT01931618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online booklet.
Description: An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
Study NCT01931618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online multi session follow-up
Description: An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group).
Study NCT02826278 — intervention group
Intervention type: OTHER
Intervention: External genitalia measurements in female newborns
Study NCT00881257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GRST Peripheral Catheter System
Description: Treatment to dilate stenoses and reduce plaque in treated vessels
Study NCT01117948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Description: Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
Study NCT03728738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head of Bed Positioning
Description: The head of bed (HOB) position will be selected through computerized randomization, and will include either zero degree positioning or thirty degree HOB elevation
Study NCT01117948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
Study NCT00233792 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: sirolimus coated Bx VELOCITY stent - fast release
Study NCT00233792 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: sirolimus coated Bx VELOCITY stent - slow release
Study NCT01835340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug: Propofol Anesthesia Patients will undergo propofol anesthesia.
Study NCT04206046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anaesthesia
Description: Patients will receive a spinal anaesthetic
Study NCT04206046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia
Description: patients will receive a general anaesthetic and a femoral nerve block
Study NCT02492464 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red yeast rice
Description: 1 capsule to be taken before to sleep, each day, for 6 months
Study NCT02492464 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04667988 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: JAK expression
Description: JAK2 assessment in blood by PCR
Study NCT02454543 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radical prostatectomy
Description: Study participants randomized in the intervention arm receive best systemic therapy in addition to radical prostatectomy with extended lymphadenectomy. It is not crucial whether the radical prostatectomy is performed open or robot-assisted.
Study NCT02454543 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Best systemic therapy
Description: For the antiandrogenic therapy a non-steroidal antiandrogen (e.g. flutamide, bicalutamide) or a gonadotropin-releasing hormone (GnRH) analogues (e.g. goserelin, leuprolide) are available.~The selection of best systemic therapy is up to the judgment of the treating urologist.
Study NCT02540135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluorescein
Description: fluorescein and conventional neuro-navigation
Study NCT02540135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intraoperative MRI
Description: conventional neuro-navigation and iMRI
Study NCT02540135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intraoperative MRI
Description: conventional neuro-navigation and iMRI
Study NCT02245854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exacto™
Description: Cold snare polypectomy
Study NCT03991949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Formula fed Ad libitum
Study NCT03509285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: 0.5 mg and 1.0 mg alprazolam tablets
Study NCT03509285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: 100 mg tablet
Study NCT03396588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: 1mcg/kg/dose (with a dosing interval of 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
Study NCT03396588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Starting dose is 0.06 mg/kg/dose (every 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
Study NCT06024343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MPD Exposure, Repair or Reconstruction
Description: During laparoscopic or robotic pancreatic tumor enucleation, if the main pancreatic duct (MPD) is injured due to its proximity or encasement by the tumor, MPD manipulation is performed. MPD manipulation is categorized into three scenarios: exposed but not injured; simple suture repair (using 5-0/6-0 PROLENE polypropylene suture); and suture repair/reconstruction following stent insertion. Using the F6 ventricular drainage catheter with 1-2 side holes trimmed as the stent, typically requiring 10 cm for passage through the duodenal papilla and 3-4 cm if not passing through. Following stent placement, intermittent suturing reconstructs the MPD, with one stitch securing the stent by passing through both the stent side wall and the MPD.
Study NCT03340506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: dabrafenib is available in capsules (50mg and 75mg) taken twice a day
Study NCT03340506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: trametinib is available in tablets (0.5mg, 2mg dose)
Study NCT02543385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S Ketamine
Description: S+ketamine will be given in group I only in the doses of 0.25mg/kg (iv bolus) before induction along with midazolam and 0. 25 mg/kg (iv bolus) 20 minutes prior to extubation
Study NCT02543385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S Ketamine
Description: S+ketamine will be given in group I only in the doses of 0.25mg/kg (iv bolus) before induction along with midazolam and 0. 25 mg/kg (iv bolus) 20 minutes prior to extubation
Study NCT03489083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training was performed three times per week for twelve weeks. Supervised (by qualified sport and exercise scientists) exercise was performed in a gym on three non-consecutive days of the week. Each session lasted \~60 min and consisted of a warm up, the resistance exercise training and a cool down. The training programme consisted of a combination of upper and lower body exercises using gym equipments, free weights and body weight as the primary resistance. The twelve weeks of strength training were divided into three mesocycles of four weeks each. The resistance training was performed using two to three sets per exercise at intensities between 12-15 repetition maximum-RM.
Study NCT03489083 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Training
Description: Control group performed a placebo stretching/relaxing session once a week (for adherence purposes) for twelve weeks. To avoid any significant adaptation, all stretching exercises (for large muscle groups only) were performed at very low intensity without any significant discomfort.
Study NCT00396370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG strain Connaught
Description: Connaught strain Bacillus Calmette-Guerin (BCG), 8-32 x 10\^5 CFU vaccine for intradermal administration.
Study NCT02504710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinematic Real Time Feedback
Study NCT02504710 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional systems of manual therapy teaching
Study NCT02592122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol Aerosol
Study NCT02592122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No drugs
Study NCT00396370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG strain Danish
Description: Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 1.2 X 10\^8 colony-forming units (CFU) oral (PO) in 60 mililiters phosphate buffered saline (PBS).
Study NCT03590873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Vasopressin, is a hormone synthesized as a peptide prohormone in neurons in the hypothalamus, and is converted to arginine vasopressin. It then travels down the axon of that cell, which terminates in the posterior pituitary, and is released from vesicles into the circulation in response to extracellular fluid hypertonicity (hyperosmolality). Arginine vasopressin has two primary functions. First, it increases the amount of solute-free water reabsorbed back into the circulation from the filtrate in the kidney tubules of the nephrons. Second, arginine vasopressin constricts arterioles, which increases peripheral vascular resistance and raises arterial blood pressure.
Study NCT03072732 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: u-Cor System
Description: Monitoring System
Study NCT03072732 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ZOE Fluid Status Monitor
Description: Monitoring System
Study NCT01790776 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Urografin 30%
Description: Urografin 30% (Natrium amidotrizoas 10G, Megalumin, Amidotrizoas 65G, Natrii calcii edetas, water for injection 250 ml, with 146 mg iodium/ml).~The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (urografin 30 %) is instilled.
Study NCT01790776 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: NaCl 0,9 % in aqua
Description: The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (NaCl 0,9 % in aqua) is instilled. If the result is inconclusive, urografin 30 % will be instilled.
Study NCT04082143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allograft mucosal enhancement with dental implant
Description: implant placement with allograft mucosal enhancement
Study NCT04082143 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No allograft mucosal enhancement at time of dental implant placement
Description: implant placement without allograft mucosal enhancement
Study NCT03865771 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological testing
Description: memory, executive testing, behaviour questionnaire, visual attention,
Study NCT03865771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Description: memory, executive testing, behaviour questionnaire, visual attention,
Study NCT03865771 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological procedure
Description: Rey auditory verbal learning test, Delayed recall : 1h, 5h, 24h (after one night sleep)
Study NCT03865771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological procedure
Description: Rey auditory verbal learning test, Delayed recall : 1h, 5h, 24h (after one night sleep)
Study NCT03865771 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Video EEG and polysomnography
Description: Video EEG : 10 electrodes + 3 electrodes for PSG 2h wake EEG Whole night EEG
Study NCT02467907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administration of carboplatin at 5 milligrams per milliliter\*minute (mg/mL\*min) on Day 1 every 3 weeks for at least 6 cycles
Study NCT03893175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction